| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Cory Abate-Shen | |
| Takashi Kobayashi | |||
| James M McKiernan | |||
| Tomasz B Owczarek | |||
| P2860 | cites work | Patient-derived tumour xenografts as models for oncology drug development | Q24604068 |
| Genome sequencing identifies a basis for everolimus sensitivity | Q24631915 | ||
| Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells | Q24657020 | ||
| Normal and neoplastic urothelial stem cells: getting to the root of the problem | Q26825948 | ||
| The androgen receptor and stem cell pathways in prostate and bladder cancers (review) | Q26853232 | ||
| Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib | Q27852954 | ||
| Isolation of a transforming sequence from a human bladder carcinoma cell line | Q28264736 | ||
| A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene | Q28279136 | ||
| Mutational landscape and significance across 12 major cancer types | Q28300353 | ||
| Discovery and saturation analysis of cancer genes across 21 tumour types | Q28305204 | ||
| Comprehensive molecular characterization of urothelial bladder carcinoma | Q28306864 | ||
| Susceptibility of urothelium to neoplastic cellular implantation | Q28338312 | ||
| Identification of gene expression signature modulated by nicotinamide in a mouse bladder cancer model | Q28477425 | ||
| Paradoxical roles of the immune system during cancer development | Q29614305 | ||
| Loss of SPARC in bladder cancer enhances carcinogenesis and progression | Q30422650 | ||
| Molecular credentialing of rodent bladder carcinogenesis models | Q30441327 | ||
| Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder | Q30540440 | ||
| p53 heterozygosity results in an increased 2-acetylaminofluorene-induced urinary bladder but not liver tumor response in DNA repair-deficient Xpa mice | Q33205410 | ||
| Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development | Q33487902 | ||
| Generation of a concise gene panel for outcome prediction in urinary bladder cancer | Q33561596 | ||
| Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden | Q33568623 | ||
| Cell biology and physiology of the uroepithelium | Q33570078 | ||
| Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy | Q33572016 | ||
| Prediction of stage, grade, and survival in bladder cancer using genome-wide expression data: a validation study | Q33671702 | ||
| Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder | Q33809489 | ||
| p63 regulates commitment to the prostate cell lineage | Q33913879 | ||
| A population of progenitor cells in the basal and intermediate layers of the murine bladder urothelium contributes to urothelial development and regeneration | Q33953216 | ||
| Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer | Q38222834 | ||
| Inducible gene knockouts in the small intestinal and colonic epithelium | Q38317150 | ||
| p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. | Q38345714 | ||
| A new tumor suppressor role for the Notch pathway in bladder cancer | Q38959215 | ||
| EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype | Q38976788 | ||
| Identification of potential bladder progenitor cells in the trigone | Q39165185 | ||
| Real-time cancer cell tracking by bioluminescence in a preclinical model of human bladder cancer growth and metastasis | Q39535769 | ||
| A molecular taxonomy for urothelial carcinoma. | Q39621985 | ||
| Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis | Q39700670 | ||
| Retinoid signaling in progenitors controls specification and regeneration of the urothelium | Q39709206 | ||
| Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG. | Q39904370 | ||
| Bladder tissue formation from cultured bladder urothelium. | Q40311994 | ||
| Identification of genes correlated with early-stage bladder cancer progression | Q40897221 | ||
| A model of bladder tumor xenografts in the nude rat. | Q41278970 | ||
| Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis | Q41584915 | ||
| Urinary bladder carcinogenesis | Q41720983 | ||
| K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder. | Q41788062 | ||
| Effective utilization and appropriate selection of genetically engineered mouse models for translational integration of mouse and human trials | Q41886748 | ||
| Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice | Q42214617 | ||
| The recovery of mouse bladder epithelium after injury by 4-ethylsulphonylnaphthalene-1-sulphonamide | Q42234038 | ||
| Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer | Q42275760 | ||
| Accelerated induction of bladder cancer in patched heterozygous mutant mice | Q42458720 | ||
| Bladder cancers arise from distinct urothelial sub-populations. | Q42465565 | ||
| The human urothelium consists of multiple clonal units, each maintained by a stem cell | Q42491329 | ||
| Changing patterns of keratin expression could be associated with functional maturation of the developing human bladder | Q42523966 | ||
| Controlling gene expression in the urothelium using transgenic mice with inducible bladder specific Cre-lox recombination | Q42528004 | ||
| In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer. | Q42550010 | ||
| Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer | Q43718966 | ||
| Bladder permeability barrier: recovery from selective injury of surface epithelial cells | Q44058255 | ||
| Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. | Q44068643 | ||
| Role of mesenchymal-epithelial interactions in normal bladder development | Q45075330 | ||
| Loss of SPARC in bladder cancer enhances carcinogenesis andprogression. | Q45753237 | ||
| Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation | Q45823928 | ||
| Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. | Q45967681 | ||
| Accumulation of nuclear p53 and tumor progression in bladder cancer. | Q45977663 | ||
| Urothelial overexpression of insulin-like growth factor-1 increases susceptibility to p-cresidine-induced bladder carcinogenesis in transgenic mice. | Q46025424 | ||
| Thioredoxin-interacting protein suppresses bladder carcinogenesis | Q46065918 | ||
| Intravesical administration of plasminogen activator inhibitor type-1 inhibits in vivo bladder tumor invasion and progression | Q46245646 | ||
| Ontogeny of the rat bladder: smooth muscle and epithelial differentiation | Q46440757 | ||
| Susceptibility of p27 kip1 knockout mice to urinary bladder carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine may not simply be due to enhanced proliferation | Q46890180 | ||
| Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner | Q46952728 | ||
| Tissue-specific mutagenesis by N-butyl-N-(4-hydroxybutyl)nitrosamine as the basis for urothelial carcinogenesis. | Q51377445 | ||
| Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. | Q51703160 | ||
| Identifying distinct classes of bladder carcinoma using microarrays. | Q52111529 | ||
| Mutational context and diverse clonal development in early and late bladder cancer. | Q53144252 | ||
| Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue. | Q53342271 | ||
| High susceptibility of p53(+/-) knockout mice in N-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. | Q53431259 | ||
| Frequent mutations of the p53 gene and infrequent H- and K-ras mutations in urinary bladder carcinomas of NON/Shi mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine | Q53460931 | ||
| Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. | Q54583947 | ||
| Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. | Q54675021 | ||
| Optimizing Orthotopic Bladder Tumor Implantation in a Syngeneic Mouse Model | Q57823688 | ||
| Single and combination chemotherapy for primary murine bladder cancer | Q67241460 | ||
| Histological classification of urinary bladder cancers in rats induced by N-butyl-n-(4-hydroxybutyl)nitrosamine | Q67782654 | ||
| Urothelial proliferation in growing mice | Q69485447 | ||
| Rapid induction of bladder cancer in rats with N-methyl-N-nitrosourea. I. Histology | Q70412985 | ||
| Morphology of the developing mammalian bladder | Q72410612 | ||
| Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation | Q73897079 | ||
| Optimizing syngeneic orthotopic murine bladder cancer (MB49) | Q77926069 | ||
| Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma | Q78029755 | ||
| SELECTIVE INDUCTION OF BLADDER CANCER IN RATS BY DIBUTYL- AND N-BUTYL-N-BUTANOL(4)-NITROSAMINE | Q78503117 | ||
| Cell proliferation and migration as revealed by radioautography after injection of thymidine-H3 into male rats and mice | Q79073344 | ||
| Differential expression of cell cycle regulators in phenotypic variants of transgenically induced bladder tumors: implications for tumor behavior | Q81448356 | ||
| Gene deletion in urothelium by specific expression of Cre recombinase | Q81666829 | ||
| Bladder cancer | Q84058686 | ||
| Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model | Q84323721 | ||
| Bladder cancer | Q86591216 | ||
| Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer | Q87126660 | ||
| Importance of orthotopic transplantation procedures in assessing the effects of transfected genes on human tumor growth and metastasis | Q36890228 | ||
| A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience | Q36979001 | ||
| History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story | Q36998789 | ||
| Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer | Q37001322 | ||
| Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression | Q37016565 | ||
| How genetically engineered mouse tumor models provide insights into human cancers | Q37065678 | ||
| Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer | Q37122307 | ||
| Inactivation of p53 and Pten promotes invasive bladder cancer | Q37141814 | ||
| Constitutive β-catenin activation induces male-specific tumorigenesis in the bladder urothelium | Q37215956 | ||
| Bone morphogenetic protein 4 signaling regulates epithelial renewal in the urinary tract in response to uropathogenic infection | Q37227229 | ||
| Molecular pathogenesis of bladder cancer | Q37243937 | ||
| Molecular pathogenesis and diagnostics of bladder cancer | Q37288841 | ||
| Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis. | Q37379450 | ||
| Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer | Q37460949 | ||
| Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis. | Q37480033 | ||
| Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer | Q37587622 | ||
| Quality of life and body image for bladder cancer patients undergoing radical cystectomy and urinary diversion--a prospective cohort study with a systematic review of literature | Q37601666 | ||
| Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology | Q37612632 | ||
| The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. | Q37647214 | ||
| Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications | Q37657206 | ||
| Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art. | Q37680509 | ||
| Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder | Q37730596 | ||
| Molecular pathways of urothelial development and bladder tumorigenesis | Q37770779 | ||
| Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium | Q37770780 | ||
| Urothelial carcinoma of the bladder: definition, treatment and future efforts | Q37944437 | ||
| Bladder cancer risk from occupational and environmental exposures | Q37990118 | ||
| Exploring molecular genetics of bladder cancer: lessons learned from mouse models | Q37994164 | ||
| Review: BBN as an urothelial carcinogen | Q38024772 | ||
| Epidemiology and risk factors of urothelial bladder cancer | Q38033265 | ||
| Current preclinical models for the advancement of translational bladder cancer research | Q38069907 | ||
| Management of superficial and muscle-invasive urothelial cancers of the bladder | Q38083129 | ||
| Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature | Q38117909 | ||
| The mechanism of action of BCG therapy for bladder cancer--a current perspective | Q38184849 | ||
| Current animal models of bladder cancer: Awareness of translatability (Review) | Q33962620 | ||
| The mammalian urinary bladder: an accommodating organ | Q34042600 | ||
| A BAC-based transgenic mouse specifically expresses an inducible Cre in the urothelium | Q34230543 | ||
| T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes | Q34253435 | ||
| Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma | Q34299788 | ||
| Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma | Q34338401 | ||
| Bladder cancer stage and outcome by array-based comparative genomic hybridization | Q34456640 | ||
| Malignant non-urothelial neoplasms of the urinary bladder: a review | Q34543531 | ||
| β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. | Q34603174 | ||
| The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer | Q34688859 | ||
| Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. | Q34698294 | ||
| A tissue-specific promoter that can drive a foreign gene to express in the suprabasal urothelial cells of transgenic mice. | Q34717264 | ||
| Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression | Q34755858 | ||
| Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy | Q34866510 | ||
| Uroplakins in urothelial biology, function, and disease | Q34973621 | ||
| Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia | Q34994908 | ||
| Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis | Q35006427 | ||
| Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma | Q35063395 | ||
| A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors | Q35072270 | ||
| An orthotopic model of murine bladder cancer | Q35396341 | ||
| Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis | Q35589281 | ||
| The health economics of bladder cancer: a comprehensive review of the published literature. | Q35642541 | ||
| Mouse models of human bladder cancer as a tool for drug discovery | Q35738385 | ||
| Three differentiation states risk-stratify bladder cancer into distinct subtypes | Q35750975 | ||
| Gene discovery in bladder cancer progression using cDNA microarrays | Q35791851 | ||
| Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model | Q35829505 | ||
| Focus on bladder cancer | Q35868630 | ||
| Association between smoking and risk of bladder cancer among men and women | Q36231850 | ||
| Urothelial tumorigenesis: a tale of divergent pathways | Q36234720 | ||
| The mighty mouse: genetically engineered mouse models in cancer drug development | Q36568461 | ||
| Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. | Q36600567 | ||
| Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model | Q36619665 | ||
| Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor. | Q36817627 | ||
| Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer | Q36823607 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bladder cancer | Q504775 |
| P304 | page(s) | 42-54 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Nature Reviews Cancer | Q641657 |
| P1476 | title | Modelling bladder cancer in mice: opportunities and challenges | |
| P478 | volume | 15 |
| Q49723795 | A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. |
| Q64977058 | A predictive nomogram for individualized recurrence stratification of bladder cancer using multiparametric MRI and clinical risk factors. |
| Q64082818 | A surgical orthotopic approach for studying the invasive progression of human bladder cancer |
| Q37306965 | Aldo-keto reductase 1C1 induced by interleukin-1β mediates the invasive potential and drug resistance of metastatic bladder cancer cells |
| Q92308894 | An improved mouse orthotopic bladder cancer model exhibiting progression and treatment response characteristics of human recurrent bladder cancer |
| Q43544386 | Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma |
| Q57788224 | BCG-induced cytokine release in bladder cancer cells is regulated by Ca signaling |
| Q91976220 | Carcinogen-induced bladder cancer in the FVB mouse strain is associated with glandular differentiation and increased Cd274/Pdl-1 expression |
| Q38808040 | Challenges with in vitro and in vivo experimental models of urinary bladder cancer for novel drug discovery. |
| Q55041956 | Comprehensive gene expression analysis of canine invasive urothelial bladder carcinoma by RNA-Seq. |
| Q28550059 | Conditional Expression of the Androgen Receptor Increases Susceptibility of Bladder Cancer in Mice |
| Q30403508 | Dynamic Change in p63 Protein Expression during Implantation of Urothelial Cancer Clusters |
| Q33798322 | Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis |
| Q64259325 | Enhanced metastatic potential in the MB49 urothelial carcinoma model |
| Q92487512 | Establishing and characterization of human and murine bladder cancer organoids |
| Q96303429 | Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture |
| Q93120435 | Establishment of a novel experimental model for muscle-invasive bladder cancer using a dog bladder cancer organoid culture |
| Q49486649 | Ex vivo culture of tumor cells from N-methyl-N-nitrosourea-induced bladder cancer in rats: Development of organoids and an immortalized cell line |
| Q64233807 | Expression of bladder cancer-associated glycans in murine tumor cell lines |
| Q63979922 | Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities |
| Q51109565 | Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1α. |
| Q41075936 | Inhibition of TGF-β signaling supports high proliferative potential of diverse p63+ mouse epithelial progenitor cells in vitro. |
| Q41339763 | Insights from animal models of bladder cancer: recent advances, challenges, and opportunities |
| Q57175925 | Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy |
| Q91761153 | Mouse and human urothelial cancer organoids: A tool for bladder cancer research |
| Q33593041 | Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs. |
| Q55081994 | Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies. |
| Q89622453 | Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans |
| Q33919192 | Optimizing mouse models for precision cancer prevention. |
| Q36177642 | Patient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic Tumors |
| Q38714374 | Patient-derived xenografts as in vivo models for research in urological malignancies |
| Q50096902 | Preclinical mouse solid tumour models: status quo, challenges and perspectives. |
| Q41273487 | Proceedings of the 3rd Annual Albert Institute for Bladder Cancer Research Symposium. |
| Q90477375 | Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder |
| Q37688331 | RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation |
| Q55397522 | Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines. |
| Q38629126 | TPX2-p53-GLIPR1 regulatory circuitry in cell proliferation, invasion and tumor growth of bladder cancer. |
| Q90221264 | The dog as an animal model for bladder and urethral urothelial carcinoma: Comparative epidemiology and histology |
| Q54936181 | Three-dimensional organoid culture reveals involvement of Wnt/β-catenin pathway in proliferation of bladder cancer cells. |
| Q55126311 | Understanding the biology of urothelial cancer metastasis. |
| Q47826917 | Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma. |
| Q39097235 | Urothelial generation and regeneration in development, injury, and cancer. |
| Q57971162 | Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity |
Search more.